Gabri Labs opens an advanced medical devices facility in Dubai Science Park
Pharmaceutical technology company Gabri Labs has announced the establishment of a local medical device manufacturing facility. The global company has signed an agreement with Dubai Science Park, a leading research community, to build a medical device manufacturing facility, reinforcing Dubai’s appeal as a global healthcare and pharmaceutical manufacturing hub, in line with the UAE government’s Operation 300bn strategy.
Leading therapeutic areas of ENT and dermatology, the new Gabri Lab facility will enable the pharmaceutical brand to produce an initial volume of 12 million units per year with further expansion by 2023. The medical products will carry the ‘Made in Emirates’ mark – a government-backed initiative to develop local manufacturing – and will be supplied to the Middle East and North Africa (MENA) markets.
Gabri Labs is a privately owned pharmaceutical company headquartered in Dover, Delaware, with manufacturing facilities in Europe and the Middle East. The brand has earned its reputation in the therapeutic ENT and dermatology fields through the development of high-quality, innovative over-the-counter medicines and medical devices. The new 10,000 sq ft facility in Dubai, with an investment of AED 18 million, will support multiple product lines and a diverse product portfolio that includes the OTOMAR ENT brand and Curadem line of dermatological solutions.
Marwan Abdulaziz Janahi, managing director of Dubai Science Park, said: “Our management’s focused efforts to develop the manufacturing sector and drive innovation through Operation 300bn are directly contributing to the improvement of Dubai’s healthcare sector. Pharmaceutical companies are increasingly choosing our emirate as a location to expand in the MENA region, backed by a favourable business environment and regulatory framework. The Dubai Science Park aims to facilitate the expansion of international companies such as Gabri Labs by continuously providing them with access to robust infrastructure, links to key regulatory bodies and a collaborative ecosystem that facilitates business creation and growth.”
Elio Gebrayel, managing director of Gabri Labs, said: “We are very excited to start a new chapter of our story in Dubai and the MENA region with the construction of our brand new facility in the emirate. The dynamic business environment and robust infrastructure of the Dubai Science Park has been instrumental in ensuring our smooth establishment, allowing us easy access to MENA’s diverse markets while participating in an active community of researchers, scientists, pharmacists and other professionals. Our new facility will enable us to serve more patients across the region and continue to innovate and lead in therapeutic ENT and dermatology.”
Gabri Labs’ expansion comes at a promising time for the UAE medical device market, which is forecast to reach AED 5.6 billion by 2025, according to US rating agency Fitch Solutions.
Gabri Labs, a global pharmaceutical technologies company, signs on with @DxbSciencePark, to develop a facility to locally produce medical devices. The new facility will enable the company to produce an initial volume of 12 million units per year.https://t.co/Hw9zsqEv9T pic.twitter.com/dk8Df3YrVc— Dubai Media Office (@DXBMediaOffice) April 5, 2022
Follow our Telegram Chanel